REHOVOT, Israel and WOBURN, Mass., May 24 /PRNewswire/ -- Rosetta
Genomics Ltd. and U.S. Genomics Inc. announced today the signing of a
discovery and co-development agreement for a microRNA-based, non-invasive
early detection test for lung cancer. This collaboration combines U.S.
Genomics' patented Trilogy(R) 2020 platform and Direct(TM) miRNA assay with
Rosetta Genomics' proprietary microRNAs. By using Rosetta Genomics' newly
discovered microRNAs as biomarkers, together with U.S. Genomics' patented
technology for sensitive molecular-level detection and quantitation, the
two companies are working to create a new molecular diagnostic test to
accurately identify lung cancer using a sputum or blood sample.
"This alliance is intended to expedite the development of
next-generation molecular diagnostic tests to identify cancer," said Amir
Avniel, CEO and president of Rosetta Genomics. "MicroRNAs hold great
promise as biomarkers for several disease states, and we are very pleased
to be working with U.S. Genomics to develop this new diagnostic tool for
patients around the world."
Approximately 30 million Americans are considered at high risk for lung
cancer. Early stage detection and treatment of lung cancer can play a role
in improving survival rates for patients. Currently available diagnostics
for lung cancer, including chest imaging (X-ray or low-dose CT) and sputum
cytology often lack the sensitivity and specificity necessary to identify
early stage disease. As a result, early-stage lung cancer may go
undiagnosed. In addition, some tests may lead to false-positive results
that can put patients at risk for unnecessary and potentially harmful
"U.S. Genomics is excited about working with Rosetta Genomics to
develop a microRNA-based diagnostic test for the early detection of lung
cancer," said John Canepa, CEO and president of U.S. Genomics. "Applying
our Trilogy(R) 2020 single molecule detection platform and our Direct(TM)
miRNA assays provide for best-in-class detection sensitivity of microRNAs
without the inherent biases of amplification-based technologies. We are
optimistic about combining these strengths with Rosetta Genomics'
proprietary microRNAs to demonstrate the potential for a significantly more
sensitive and accurate diagnostic test for this devastating disease."
About Lung Cancer
Lung cancer is the leading cause of cancer-related deaths and the
second most commonly diagnosed cancer. The American Cancer Society predicts
approximately 174,500 new cases of lung cancer in 2006 and 162,500 lung
cancer-associated deaths in the United States. Average five-year survival
rates for patients diagnosed with lung cancer are less than 15%. Five year
survival rates for patients with advanced stage IV lung cancer are only
about 5%. The population at highest risk for lung cancer includes
approximately 30 million men and women between the ages of 50 and 69 who
are current or former smokers.
MicroRNAs (miRNAs) are recently discovered, naturally occurring small
RNAs that act as regulators of protein translation. Because many diseases
are caused by the misregulated activity of proteins, the ability to
selectively regulate protein activity through microRNAs could play a role
in the treatment of many forms of cancer and other serious illnesses. In
addition, microRNAs have been shown to have different expression levels in
certain diseased versus normal tissues. As a result, microRNAs may also
play a role in helping to identify and diagnose the stage of many diseases.
About U.S. Genomics
U.S. Genomics is pioneering single molecule biology technologies for
life science and biodefense applications by combining advances in
microfluidics, optics, engineering, and novel molecular labeling
strategies. Using its DNA mapping technology, the Company is developing
sophisticated biosensors for the detection and identification of pathogens
and biomarkers in the air, human serum and other biologically relevant
materials. The Company's biodefense focus on airborne pathogens has been
funded in part by $26 million in contracts from the U.S. Department of
Defense and the U.S. Department of Homeland Security. The Company's
Trilogy(R) 2020 platform enables the direct detection and analysis of
individual molecules of DNA, RNA, and proteins without the need for
amplification. U.S. Genomics' portfolio of products will further a greater
understanding of genetics and disease pathways and will ultimately lead to
more effective therapeutics, diagnostics, and biodefense solutions. For
more information about U.S. Genomics, please visit
Trilogy(R) is a registered trademark and Direct(TM) (as in Direct
miRNA) and U.S. Genomics(TM) are trademarks of U.S. Genomics, Inc.
About Rosetta Genomics
Rosetta Genomics is a leader in the development of microRNA-based
diagnostics and therapeutics. Founded in 2000, the company's integrative
research platform combining bioinformatics and state-of-the-art laboratory
processes has led to the discovery of nearly 360 biologically validated
novel human microRNAs. Building on its strong intellectual property
position and strategic alliances with leading biotechnology companies,
Rosetta Genomics is working to develop a full range of diagnostics and
therapeutic products based on microRNAs. The company's primary therapeutic
focus is in the development of microRNA-based products to diagnose and
treat different forms of cancer.
SOURCE Rosetta Genomics Ltd.